Tabah, Alexis https://orcid.org/0000-0003-3513-2778
De Waele, Jan https://orcid.org/0000-0003-1017-9748
Ssi Yan Kai, Nathalie https://orcid.org/0000-0003-2033-5994
Aslan, Abdullah Tarik https://orcid.org/0000-0002-7844-8097
Buetti, Niccolò https://orcid.org/0000-0002-8096-1834
Timsit, Jean-François https://orcid.org/0000-0002-6063-7383
Ballard, Emma https://orcid.org/0000-0002-9430-2485
Eriksson, Lars https://orcid.org/0000-0001-5060-7706
Laupland, Kevin B. https://orcid.org/0000-0002-1205-5354
Lipman, Jeffrey https://orcid.org/0000-0002-5965-9876
Funding for this research was provided by:
The University of Queensland
Article History
Received: 30 April 2025
Accepted: 28 June 2025
First Online: 14 July 2025
Declarations
:
: Alexis Tabah has nothing to disclose, Jan De Waele has consulted for Biomerieux, Menarini, MSD, Pfizer, Roche Diagnostics, ThermoFisher and Viatris (fees and honoraria paid to institution), Nathalie Ssi Yan Kai has nothing to disclose, Abdullah Tarik Aslan has nothing to disclose, Niccolo Buetti has nothing to disclose, Jean-François Timsit reported advisory boards participation for Merck, Gilead, Beckton-Dickinson, Pfizer, Menarini, Advanz, Paratek, research grants from Merck and Pfizer, Emma Ballard has nothing to disclose, Lars Eriksson, Kevin Laupland reported grants to his research unit from Pfizer and Merck, consulting fees from Menarini, Merck, Biomerieux, Roche diagnostics advanz, all outside of the submitted work, lecture honoraria from Pfizer, Merck, Biomerieux, Shionogi, advanz, Gilead mundipharma outside of the submitted work, and support for attending meetings from Tillots. Jeffrey Lipman has nothing to disclose. Jan De Waele is supported by a Sr Clinical Research Grant from the Research Foundation Flanders (FWO, Ref. 1881020N).
: Since our scoping review did not involve human or animal studies, no ethics committee approval was required, and the study adheres to the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments.